The favourable outcomes reported for both late stage and early stage cancer from tyrosine kinase inhibitors (TKIs) targeted for EGFR mutated NSCLC highlight the importance of summarizing the frequency of such mutations among populations [4]. This evidence concerns the gene EGFR and cancer.